CD40L inhibits cell growth of THP-1 cells by suppressing the PI3K/Akt pathway.

AML-M5 CD40L P53 PCNA cell apoptosis cell proliferation cyclinD1 tumor suppressor

Journal

OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322

Informations de publication

Date de publication:
2019
Historique:
entrez: 23 5 2019
pubmed: 23 5 2019
medline: 23 5 2019
Statut: epublish

Résumé

Acute myeloid leukemia (AML), the hematological malignant tumor with high mortality, is still difficult to treat. CD40L is a type II transmembrane protein, which has been reported to have the potential to inhibit growth of some cancer cells. In order to determine the role of CD40L on AML-M5 cell line THP-1, we overexpressed CD40L in the cells using a lentiviral vector system (pHBLV-CMVIE-Zs Green-T2A-puro vector); overexpression was confirmed by the detection of green fluorescent protein and CD40L protein expression. Cellular apoptosis, proliferation, and cycle assays showed that CD40L could promote the apoptosis of, suppress the proliferation of, and stimulate the arrest of the G1/S phase of THP-1 cells. Finally, the protein expression of P53, Bax/Bcl-2, cyclinD1, PCNA, PTEN, and p-Akt illustrated that CD40L may partly influence cell growth of THP-1 cells through those genes, which was confirmed by immunohistochemistry and a PI3K/Akt activator. Taken together, CD40L could inhibit cell growth of THP-1 cells through the PI3K/Akt pathway, indicating that the overexpression of CD40L may be a potential target to treat the AML-M5 disease.

Identifiants

pubmed: 31114244
doi: 10.2147/OTT.S175347
pii: ott-12-3011
pmc: PMC6476227
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3011-3017

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

Disclosure The authors report no conflicts of interest in this work.

Références

J Pathol. 1999 May;188(1):38-43
pubmed: 10398138
Mol Pathol. 2002 Apr;55(2):110-20
pubmed: 11950960
Oncogene. 2003 Nov 27;22(54):8671-6
pubmed: 14647461
Leukemia. 2005 Apr;19(4):524-30
pubmed: 15674425
Cancer Res. 2005 Jul 1;65(13):5898-906
pubmed: 15994968
Leuk Res. 2008 Feb;32(2):269-73
pubmed: 17689610
Int J Oncol. 2010 Oct;37(4):935-41
pubmed: 20811715
Oncol Rep. 2012 Jul;28(1):262-8
pubmed: 22552529
Blood. 2013 Mar 28;121(13):2424-31
pubmed: 23325837
Basic Res Cardiol. 2013 Nov;108(6):386
pubmed: 24061433
Paediatr Drugs. 2014 Apr;16(2):151-68
pubmed: 24158739
J Biol Chem. 2014 Mar 7;289(10):7109-20
pubmed: 24474685
Tumour Biol. 2014 Oct;35(10):9447-57
pubmed: 25117071
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Curr Cancer Drug Targets. 2014;14(7):610-20
pubmed: 25163469
Expert Rev Hematol. 2014 Dec;7(6):807-18
pubmed: 25227702
Blood. 2015 Jan 29;125(5):767-74
pubmed: 25515963
Cell Mol Life Sci. 2015 Jun;72(12):2337-47
pubmed: 25712020
Cancer Treat Rev. 2015 May;41(5):431-40
pubmed: 25843228
Tumour Biol. 2015 Nov;36(11):8697-702
pubmed: 26047605
Cancer. 2015 Aug 15;121(16):2689-704
pubmed: 26095886
JAMA Oncol. 2015 Sep;1(6):820-8
pubmed: 26181162
Neuro Oncol. 2015 Nov;17(11):1428-30
pubmed: 26206773
Cell Death Dis. 2016 Mar 17;7:e2146
pubmed: 26986513

Auteurs

Zhongxin Feng (Z)

Department of Hematology, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China, 3341148215@qq.com.
Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Qi Chen (Q)

Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Mingqiang Ren (M)

Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Zuguo Tian (Z)

Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Yuping Gong (Y)

Department of Hematology, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China, 3341148215@qq.com.

Classifications MeSH